Caregiving resources for every stage of the disease.
RSS Feed Print
Another major drug fails in clinical trials
Posted: Thursday, June 7, 2018 10:26 AM
Joined: 2/26/2016
Posts: 96

Atabecestat has become another Alzheimer's drug that has failed in clinical trials. Following an evaluation of liver safety data from its studies, Johnson and Johnson has decided not to continue development of this drug.

I think that big pharma is now realizing that beta amyloid treatments may not be the answer, and that genetically modified mice are not a good model for Alzheimer's. In my opinion, treating inflammation that increases with age will lead to an effective treatment. 

Janssen pulls plug on Alzheimer’s candidate - PharmaTimes 

Posted: Tuesday, June 12, 2018 12:59 PM
Joined: 4/21/2018
Posts: 21

My mother is taking memantine, and her cognition has increased somewhat. Although it's not a cure it has helped her with daily living
Lane Simonian
Posted: Wednesday, June 13, 2018 10:18 AM
Joined: 12/12/2011
Posts: 4262

Adding to the list of anti-amyloid drug failures for Alzheimer's disease:

Amyloid does no damage to the brain unless it causes oxidation and inflammation and the way it does so is through protein kinase C activation and NMDA receptor activation (memantine is a weak NMDA receptor antagonist).

"Malinow’s team found that when mice are missing the PKC alpha gene, neurons functioned normally, even when amyloid beta was present. Then, when they restored PKC alpha, amyloid beta once again impaired neuronal function. In other words, amyloid beta doesn’t inhibit brain function unless PKC alpha is active."

Limit oxidation and inflammation and you have a chance to treat Alzheimer's disease.

Lane Simonian
Posted: Wednesday, June 13, 2018 10:29 AM
Joined: 12/12/2011
Posts: 4262

I will add this: there are dozens of factors that cause oxidation and inflammation in the brain.  Focusing on one such as amyloid was bound to fail.
× Close Menu